Cookie Consent by PrivacyPolicies.com

Publicaciones científicas

11 Publicaciones científicas disponibles

  • Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    18 de febrero de 2020 | Revista: Gynecologic Oncology

    O'Malley DM (1), Matulonis UA (2), Birrer MJ (3), Castro CM (4), Gilbert L (5), Vergote I (6), Martin LP (7), Mantia-Smaldone GM (8), Martin AG (9), Bratos R (10), Penson RT (11), Malek K (12), Moore KN (13).

    (1) The Ohio State University, Columbus, OH, United States.
    (2) Dana Farber Cancer Institute, Boston, MA, United States.
    (3) University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, United States. 
    (4) Massachusetts General Hospital, Boston, MA, United States.
    (5) McGill University Health Centre, Montreal, QC, Canada. 
    (6) Leuven Cancer Institute, Leuven, Belgium.
    (7) University of Pennsylvania, Philadelphia, PA, United States.
    (8) Fox Chase Cancer Center, Philadelphia, PA, United States.
    (9) Clinica Universidad de Navarra, Madrid, Spain.
    (10) MD Anderson Cancer Center Madrid, Madrid, Spain.
    (11) Massachusetts General Hospital, Boston, MA, United States. 
    (12) ImmunoGen, Inc., Waltham, MA, United States.
    (13) Stephenson Cancer Center at the University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Sarah Cannon Research Institute, Nashville, TN, United States.


  • Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

    28 de septiembre de 2019 | Revista: The New England Journal of Medicine

    Antonio González-Martín, M.D., Ph.D., Bhavana Pothuri, M.D., Ignace Vergote, M.D., Ph.D., René DePont Christensen, Ph.D., Whitney Graybill, M.D., Mansoor R. Mirza, M.D., Colleen McCormick, M.D., M.P.H., Domenica Lorusso, M.D., Ph.D., Paul Hoskins, M.D., Gilles Freyer, M.D., Klaus Baumann, M.D., Kris Jardon, M.D., et al., for the PRIMA/ENGOT-OV26/GOG-3012 Investigators*

    From Grupo Español de Investigación en Cáncer de Ovario (GEICO) and the Medical Oncology Department, Clínica Universidad de Navarra (A.G.-M.) and GEICO and Hospital Universitario La Paz-IdiPAZ (A.R.), Madrid, GEICO and Medical Oncology, Catalan Institute of Oncology, Girona Biomedical Research Institute, and the Department of Medical Sciences, Medical School University of Girona, Girona (P.B.-G.), and GEICO and Hospital Universitario Reina Sofía, Cordoba (M.J.R.-P.) - all in Spain; the Gynecologic Oncology Group (GOG) and the Department of Obstetrics/Gynecology, Perlmutter Cancer Center, NYU Langone Health (B.P.), and GOG and the Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College (R.E.O.), New York, and US Oncology Research (USOR) and the Division of Gynecologic Oncology, Wilmot Cancer Institute, Department of Obstetrics and Gynecology, University of Rochester, Rochester (R.G.M.) - all in New York; Belgium and Luxembourg Gynecologic Oncology Group (BGOG) and the Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University Hospitals Leuven, Leuven Cancer Institute, Leuven (I.V.), BGOG and the Department of Medical Oncology and Hematology, AZ Maria Middelares, Ghent (C.V.), and the Department of Molecular Imaging, Pathology, Radiotherapy, and Oncology, Center for Oncological Research, Antwerp University, Antwerp (C.V.) - all in Belgium; the Nordic Society of Gynecologic Oncology (NSGO) and the Research Unit of General Practice, Institute of Public Health, University of Southern Denmark, Odense (R.D.C.), NSGO and Rigshospitalet-Copenhagen University Hospital, Copenhagen (M.R.M.), and NSGO and the Department of Oncology, Aalborg University, Aalborg (B.L.) - all in Denmark; GOG and Gynecologic Oncology, Medical University of South Carolina, Charleston (W.G.); GOG and Legacy Medical Group Gynecologic Oncology, Portland, OR (C.M.); Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO) and Fondazione IRCCS National Cancer Institute of Milan (D.L.), and MITO and the Department of Obstetrics and Gynecology, San Raffaele Scientific Institute (G.M.) - both in Milan; USOR and the Department of Medical Oncology, BC Cancer, Vancouver, BC (P.H.), and GOG and the Department of Obstetrics and Gynecology, McGill University, and the Department of Oncology, McGill University Health Centre, Division of Gynecologic Oncology, Montreal (K.J.) - all in Canada; Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens and Service d'Oncologie Médicale, Centre Hospitalier Lyon-Sud, Lyon, France (G.F.); Arbeitsgemeinschaft Gynäkologische Onkologie and the Department of Gynecology and Obstetrics, Klinikum der Stadt Ludwigshafen, Ludwigshafen, Germany (K.B.); the Division of Gynecologic Oncology, Ohio State University, Columbus (F.B.); GOG and the Division of Gynecologic Oncology, University of Pennsylvania, Philadelphia (A.F.H.), and GOG and Hanjani Institute for Gynecologic Oncology, Asplundh Cancer Pavilion, Abington Jefferson Hospital, Sidney Kimmel Medical College of Thomas Jefferson University, Willow Grove (M.S.S.) - all in Pennsylvania; GOG and the Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee (W.H.B.); Israeli Society of Gynecologic Oncology and Department of Gynecology and Gynecologic Oncology, Hillel Yaffe Medical Center, Technion Israel Institute of Technology, Haifa, Israel (I.B.); GlaxoSmithKline/Tesaro, Waltham, MA (K.S., I.A.M., Y.L., D.G.); and Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine, Phoenix (B.J.M.).


  • Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer

    15 de agosto de 2019 | Revista: International Journal of Gynecological Cancer

    Lorusso D (#1), Hilpert F (#2,3), González Martin A (4,5), Rau J (6), Ottevanger P (7), Greimel E (8), Lück HJ (9), Selle F (10), Colombo N (11), Kroep JR (12), Mirza MR (13), Berger R (14), Pardo B (15), Grischke EM (16), Berton-Rigaud D (17), Martinez-Garcia J (18), Vergote I (19), Redondo A (20), Cardona A (21), Bastière-Truchot L (21), du Bois A (22), Kurzeder C (22,23); PENELOPE trial investigators.

    (1) Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy
    (2) Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany (affiliation when work was performed).
    (3) Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany.
    (4) Grupo Español de Investigación en Cáncer de Ovario (GEICO) and MD Anderson Cancer Center Spain, Madrid, Spain (affiliation when work was performed).
    (5) Clínica Universidad de Navarra, Madrid, Spain.
    (6) Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.
    (7) Dutch Gynaecological Oncology Group (DGOG) and Department of Medical Oncology, Radboud University Medical Center, Nijmegen, Netherlands.
    (8) Medical University Graz, Graz, Austria.
    (9) AGO and Gynäkologisch-Onkologische Praxis am Pelikanplatz, Hannover, Germany.
    (10) Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), Groupe Hospitalier Diaconesses Croix Saint-Simon and Alliance Pour la Recherche en Cancérologie, Paris, France.
    (11) Mario Negri Gynecologic Oncology (MaNGO) group, IEO, European Institute of Oncology IRCCS, and University of Milan-Bicocca, Milan, Italy.
    (12) DGOG and Department of Medical Oncology, Leids Universitair Medisch Centrum, Leiden, Netherlands.
    (13) Nordic Society of Gynaecological Oncology (NSGO) and Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
    (14) AGO-Austria and University Hospital for Gynaecology and Obstetrics, Medical University of Innsbruck, Innsbruck, Austria.
    (15) GEICO and Medical Oncology Department, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
    (16) AGO and University Hospital of Gynecology and Obstetrics, Tübingen, Germany.
    (17) GINECO and Integrated Center for Oncology Nantes-Angers, Nantes, France.
    (18) GEICO and Medical Oncology Service, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Spain.
    (19) AGO and Leuven Cancer Institute, University Hospital Leuven, Leuven, Belgium.
    (20) GEICO and Medical Oncology Department, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain.
    (21) F. Hoffmann-La Roche, Basel, Switzerland.
    (22) AGO and Kliniken Essen Mitte, Essen, Germany.
    (23) Department of Gynecology and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
    #Contributed equally


  • Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer

    5 de agosto de 2019 | Revista: International Journal of Cancer

    Ray-Coquard I (1), Cibula D (2), Mirza MR (3), Reuss A (4), Ricci C (5), Colombo N (6), Koch H (7), Goffin F (8), González-Martin A (9), Ottevanger PB 10, Baumann K (11), Bjørge L (12), Lesoin A (13), Burges A (14), Rosenberg P (15), Gropp-Meier M (16), Harrela M (17), Harter P (18), Frenel JS (19), Minarik T (20), Pisano C (21), Hasenburg A (22), Merger M (23), du Bois A (18); AGO Study Group-led GCIG/ENGOT Intergroup Consortium.

    (1) GINECO and Medical Oncology Department, Centre Léon Bérard, University Claude Bernard Lyon, Lyon, France.
    (2) AGO and Oncogynecologic Center, Department of Obstetrics and Gynecology, General Faculty Hospital, Charles University of Prague, Prague, Czech Republic.
    (3) NSGO and Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
    (4) AGO and Coordinating Center for Clinical Trials, Philipps-University of Marburg, Marburg, Germany.
    (5) MITO and Division of Gynecologic Oncology, Department of Women and Children's Health and Public Health, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.
    (6) MaNGO and European Institute of Oncology and University of Milan Bicocca, Milan, Italy.
    (7) AGO Austria and Department of Obstetrics and Gynecology, Paracelsus Medical University, Salzburg, Austria.
    (8) BGOG and CHU de Liège, University of Liège, Liège, Belgium.
    (9) GEICO and Medical Oncology Department, Clínica Universidad de Navarra, Madrid, Spain.
    (10) DGOG and Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.
    (11) AGO and Department of Gynecology, Klinikum der Stadt Ludwigshafen GmbH, Ludwigshafen, Germany.
    (12) NSGO and Department of Gynecology, Haukeland Universitetssykehus, Bergen, and Center for Cancer Biomarkers CCBIO, Department of Clinical Science, University of Bergen, Bergen, Norway.
    (13) GINECO and Department of Gynecologic Cancer and Medical Oncology, Centre Oscar Lambret, Lille, France.
    (14) AGO and Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Germany.
    (15) NSGO and Department of Oncology, University Hospital Linköping, Linköping, Sweden.
    (16) AGO and Department of Gynecology and Obstetrics, Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Germany.
    (17) NSGO and Department of Gynoncology and Gynecology and Obstetrics, Kymenlaakso Central Hospital, Kotka, Finland.
    (18) AGO and Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte, Essen, Germany.
    (19)GINECO and Centre René Gauducheau, Institut de Cancerologie de l'Ouest, Saint Herblain, France.
    (20) NSGO and National Institute of Oncology, Bratislava, Slovakia.
    (21) MITO and Department of Uro-Gynecologic Oncology, Istituto Nazionale per Io Studio e la Cura dei Tumori 'Fondazione G. Pascale' IRCCS, Napoli, Italy.
    (22) AGO and Department of Obstetrics and Gynecology, University Medical Center, Mainz, Germany.
    (23) Oncology Medicine, Boehringer Ingelheim International GmbH, Biberach, Germany.

No hay más publicaciones científicas

No hay más páginas para cargar